Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$39.24 USD

39.24
1,175,687

-0.71 (-1.78%)

Updated Oct 1, 2024 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 12% (30 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Halozyme (HALO) Q1 Earnings Miss, Royalties Aid Y/Y Revenues

by Zacks Equity Research

Halozyme (HALO) first-quarter earnings and sales miss estimates. Strong demand for the partnered drug, subcutaneous Darzalex, boosts the top line.

ImmunoGen (IMGN) Q1 Earnings and Sales Outpace Estimates

by Zacks Equity Research

ImmunoGen (IMGN) reports a narrower-than-expected loss for first-quarter 2022. It also beats revenue estimates.

Prothena (PRTA) Q1 Earnings Beat, Pipeline Progress in Focus

by Zacks Equity Research

Prothena beats on earnings and revenues in the first quarter of 2022. The company's progress with its AD pipeline is encouraging.

Puma Biotech (PBYI) Q1 Earnings Beat, Nerlynx Sales Fall Y/Y

by Zacks Equity Research

Puma Biotech (PBYI) Q1 loss narrows while sales come in line with estimates. PBYI's stock declines in the after-market trading session following the news.

    Sarepta (SRPT) Q1 Earnings Beat, DMD Drugs' Sales Robust

    by Zacks Equity Research

    Strong demand for Sarepta's (SRPT) DMD drugs boosts its top line in the first quarter. Stock up in after-market trading.

    Blueprint Medicines (BPMC) Q1 Loss in Line, Revenues Top Mark

    by Zacks Equity Research

    Blueprint Medicines' (BPMC) earnings meet estimates while revenue beat the same for the first quarter of 2022. Stock up.

    Regeneron (REGN) Q1 Earnings Beat, COVID Antibody Sales Affected

    by Zacks Equity Research

    Regeneron (REGN) beats on Q1 earnings and sales record year-over-year growth on the solid performance of Dupixent and Eylea.

    Biogen (BIIB) Q1 Earnings Miss, Aduhelm Setback Leads to Rejig

    by Zacks Equity Research

    Biogen (BIIB) misses first-quarter estimates for earnings but beats the same for sales. Following no medicare beneficiary access to Aduhelm, Biogen initiates a cost-savings program.

    Seagen's (SGEN) Q1 Earnings & Revenues Surpass Estimates

    by Zacks Equity Research

    Seagen (SGEN) reports narrower-than-expected loss in the first quarter of 2022 while its revenues beat estimates.

    Amgen's (AMGN) Q1 Earnings Top, Stock Down on IRS Tax Dispute

    by Zacks Equity Research

    Amgen (AMGN) beats Q1 estimates for earnings and sales. The stock declines on the announcement of litigation and tax dispute with the IRS.

    Will Biogen (BIIB) Succeed in Beating Q1 Earnings Estimates?

    by Zacks Equity Research

    Biogen's (BIIB) multiple sclerosis revenues have been declining since the past few quarters. It is unlikely that MS sales have improved in the first quarter.

    Novartis (NVS) Beats on Q1 Earnings, Sandoz Posts Growth

    by Zacks Equity Research

    Novartis (NVS) beats on earnings in the first quarter but sales lag expectations. Generic Sandoz business returns to growth.

    Is a Beat Likely for AbbVie (ABBV) This Earnings Season?

    by Zacks Equity Research

    AbbVie's (ABBV) first-quarter results are expected to reflect the impact of strong demand for immunology drugs, aesthetics and cosmetics products. Investors are likely to focus on any update related to Humira LOE.

    Roche's (RHHBY) Q1 Sales Grow on COVID-19 Tests, New Drugs

    by Zacks Equity Research

    Roche (RHHBY) performance in the first quarter was encouraging, driven by demand for COVID-19 tests and contribution from newer drugs.

    Halzoyme (HALO) Up 8.3% YTD: Will It Continue to Trend Higher?

    by Zacks Equity Research

    Halozyme's (HALO) revenues are driven by strong demand for new partnered drugs. Restructuring initiatives are boosting margins. Robust revenue growth is expected to continue in 2022.

      The Zacks Analyst Blog Highlights Johnson & Johnson, Roche Holding, Raytheon Technologies, Intuit and Target

      by Zacks Equity Research

      Johnson & Johnson, Roche Holding, Raytheon Technologies, Intuit and Target have been included in this Analyst Blog.

      Sheraz Mian headshot

      Top Research Reports for Johnson & Johnson, Roche & Raytheon

      by Sheraz Mian

      Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Roche Holding AG (RHHBY), and Raytheon Technologies Corporation (RTX).

      Prothena (PRTA) Stock Gains 51% in a Year: What Lies Ahead?

      by Zacks Equity Research

      Prothena (PRTA) has had a phenomenal run in the past year, primarily due to its promising pipeline for AD.

      Kinjel Shah headshot

      Pharma Stock Roundup: PFE to Buy RSV Drugmaker, FDA Updates for NVS, MRK and RHHBY

      by Kinjel Shah

      Pfizer (PFE) announces plans to acquire ReViral for up to $525 million. Merck (MRK), Novartis (NVS) and Roche (RHHBY) provide FDA updates.

      Biogen (BIIB) Down as Medicare Limits Coverage for Aduhelm

      by Zacks Equity Research

      Biogen (BIIB) stock declines after Medicare limits coverage for FDA-approved Alzheimer's drugs like Aduhelm only for patients enrolled in CMS-approved studies.

      Regeneron (REGN), Sanofi's Dupixent Gets EU Nod for Asthma in Kids

      by Zacks Equity Research

      Regeneron (REGN) and Sanofi's (SNY) Dupixent receives label expansion in the European Union for severe asthma with type 2 inflammation in children aged between 6 years and 11 years.

      Halozyme's (HALO) ENHANZE Drives Sales Amid Rising Competition

      by Zacks Equity Research

      Halozyme (HALO) is attracting partnerships from several large pharma companies as well as biotechs, courtesy of its ENHANZE technology. Royalties and product supply to partners are likely to drive revenues.

      Roche (RHHBY) Actemra Application Receives Priority Review

      by Zacks Equity Research

      Roche (RHHBY) sBLA is seeking approval for the intravenous formulation of arthritis drug Actemra accepted and granted Priority Review in the United States.

      Kinjel Shah headshot

      Pharma Stock Roundup: FDA Nod for 2nd COVID Booster, New Approvals for AZN, GSK, NVS

      by Kinjel Shah

      FDA authorizes second booster dose of PFE and MRNA COVID-19 vaccines for older adults. RHHBY's late-stage study for ES-SCLC fails.

      Biogen (BIIB) Plans to Start Aduhelm Confirmatory Study in May

      by Zacks Equity Research

      Biogen (BIIB) expects to start the phase IV post-marketing confirmatory study of Aduhelm for Alzheimer's disease in May 2022. The estimated completion period of the study is four years.